GlassScriptPhysician profile
Maria Javaid
NPI 1679886618
$1,894.64
in general payments reported to CMS, 2019-2025
26 companies · $487 in 2025
The $487 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $561 · 2023: $451 · 2024: $396 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $484.58 | 2022-2025 | Minimed 780g, Simplera Sensor, Inpen Smart Insulin Delivery System |
| Abbott Laboratories | $184.60 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Amgen INC. | $145.73 | 2022-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $141.18 | 2022-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $133.65 | 2022-2025 | |
| Abbvie INC. | $88.64 | 2023-2025 | |
| Averitas Pharma INC. | $88.40 | 2023-2025 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $83.37 | 2022-2023 | |
| Dexcom, INC. | $63.20 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $54.83 | 2023-2025 | Gvoke Hypopen |
| Antares Pharma, INC. | $48.21 | 2022 | |
| Insulet Corporation | $44.01 | 2022-2023 | Omnipod |
| Cequr Corporation | $38.16 | 2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.64 | 2022-2024 | Jardiance |
| Nevro Corp. | $34.03 | 2023-2024 | Senza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $32.09 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $29.65 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $29.56 | 2024 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $20.57 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $19.40 | 2022 | |
| Janssen Biotech, INC. | $18.86 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.98 | 2022 | |
| Lilly USA, LLC | $15.97 | 2022 | |
| Eisai INC. | $15.19 | 2022 | |
| Ascendis Pharma Endocrinology INC | $14.69 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Javaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.